Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
An RX mirror and its underlying label are not independent clinical confirmations.
Check source scope before reading a dose
ELAHERE: selected primary-label renal guidance and limits
Product / population
Adult IV ELAHERE for labeled biomarker-selected ovarian/fallopian/peritoneal cancer; renal guidance does not replace adjusted-ideal-body-weight dosing.
Renal method
CrCl, mL/min; use section 8.6 category boundaries
Source revision
Revision date not captured in selected review; retrieval date is not revision date.
Retrieved
2026-11-07
Local review status
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
ELAHERE: source applicability and renal evidence limits
CrCl 15 to <30 and ESRD: effects unknown; dialysis dosing not established. The RX mirror is not independent corroboration of the matched label.
What to reconcile: Confirm dosing-weight method and ocular safety requirements.
DailyMed / product prescribing information · Adult IV ELAHERE for labeled biomarker-selected ovarian/fallopian/peritoneal cancer; renal guidance does not replace adjusted-ideal-body-weight dosing.
Renal method: CrCl, mL/min; use section 8.6 category boundaries Source date: Revision date not captured in selected review; retrieval date is not revision date. Retrieved: 2026-11-07
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
CrCl 15 to <30 and ESRD: effects unknown; dialysis dosing not established.
Dialysis evidence: No dialysis regimen established in selected content
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Section 8.6; dosing and ocular-warning context
No renal adjustment is recommended at CrCl 30-89 mL/min. Effects at CrCl 15 to <30 and in ESRD are unknown. No dialysis regimen is established. Retain the labeled dosing-weight method and required ocular examinations, prophylaxis and toxicity management.
RDM72-mirvetuximab-elahere-label-1 · Source locator: Section 8.6; dosing and ocular-warning context
Source-specific limits
Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
